Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease
Status:
Completed
Trial end date:
2020-11-18
Target enrollment:
Participant gender:
Summary
This is a global Phase III, randomized, double-blinded, placebo-controlled study for subjects
with evidence of early AD. The protocol is designed to determine whether ALZT-OP1 combination
treatment (ALZT-OP1a + ALZT-OP1b) will slow down, arrests, or reverse cognitive and
functional decline, in subjects with evidence of early stage Alzheimer's disease (AD).
Phase:
Phase 3
Details
Lead Sponsor:
AZTherapies, Inc.
Collaborators:
APCER Life Sciences KCAS Bio PharmaConsulting Group